Livmarli

ApprovedSmall molecule

MMirum Pharmaceuticals, Inc.

Livmarli is one of 2 small molecule programs targeting Alagille Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alagille SyndromeRecruiting

Alagille SyndromeApproved

Recruiting

Competition

Competitive Landscape

1 competitor in Alagille Syndrome

#DrugCompanyPhaseTrials

Bylvay

Ipsen

Phase 3

1 2

Livmarli

MMirum Pharmaceuticals, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Recruiting

Outcome

NCT06193928

Q4 2030

ApprovedRecruiting

Alagille Syndrome

NCT07290257

Clinical

Trials by Indication[1]

Outcome1 trial

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Recruiting·MMirum Pharmaceuticals, Inc.··NCT06193928·70 enrolled

Alagille Syndrome1 trial

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Recruiting·MMirum Pharmaceuticals, Inc.·Approved·NCT07290257·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Livmarli. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Livmarli compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Livmarli. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirum Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMirum Pharmaceuticals, Inc.

Livmarli

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q4 2030

Trials by Indication[1]

Outcome1 trial

Alagille Syndrome1 trial

References

Drug Info

Quick Facts

Related News